文献速递肝胆胰外科围术期管理与 ERAS

腹膜冲洗细胞学阳性对可切除胰腺导管腺癌预后的影响:日本全国癌症登记研究

Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
PubMed 文献 · Surgery · 2019-08-21

本研究基于日本胰腺癌登记数据库,分析1,970例接受肿瘤切除的胰腺导管腺癌患者,其中细胞学阳性106例、阴性1,864例。阳性组腹膜复发比例更高(43% vs 14%,P<.001),中位总生存期更短(17.5个月 vs 29.4个月,P<.001),5年生存率分别为13.7%和31.1%。多因素分析显示辅助化疗是阳性组独立预后因素,阳性细胞学不排除治愈性切除可能。

要点

  • 细胞学阳性组中位生存17.5个月,阴性组29.4个月(P<.001)。
  • 阳性组腹膜复发比例43%,阴性组14%(P<.001)。
  • 辅助化疗是细胞学阳性患者独立预后因素。

核心结论

  • 腹膜冲洗细胞学阳性是胰腺导管腺癌切除术后不良预后因素,但不排除尝试治愈性切除。
  • 治愈性切除后辅以辅助化疗可能有助于改善细胞学阳性患者的长期预后。

研究设计与样本

  • 日本全国癌症登记为基础的回顾性研究,纳入1,970例接受肿瘤切除的胰腺导管腺癌患者。
  • 分析临床病理因素和总生存曲线,采用多因素Cox比例风险模型评估预后因素。

主要发现

  • 细胞学阳性组106例,阴性组1,864例。
  • 阳性组胰体尾癌频率更高、术前血清CA19-9水平更高(各P<.001)。
  • 阳性组腹膜复发比例43%,阴性组14%(P<.001)。
  • 阳性组中位总生存期17.5个月,阴性组29.4个月(P<.001)。
  • 阳性组5年生存率13.7%,阴性组31.1%。

临床怎么用

  • 对细胞学阳性但肿瘤可切除的患者,不应仅因细胞学阳性放弃治愈性切除。
  • 细胞学阳性患者切除后应重视辅助化疗以改善长期预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The importance of peritoneal washing cytology status both as a sign of irresectability and as a prognostic factor for pancreatic ductal adenocarcinoma remains controversial. The purpose of this nationwide, cancer registry-based study was to clarify the clinical implications of operative resection in patients who had positive cytology status. METHODS: Clinical data from 1,970 patients who underwent tumor resection were collected from the Pancreatic Cancer Registry in Japan. Clinicopathologic factors and overall survival curves were analyzed, and multivariate Cox proportional hazard models were evaluated. RESULTS: Among the 1,970 patients analyzed, positive cytology status was found in 106 patients and negative cytology status was found in 1,864 patients. The positive cytology status group had a greater frequency of pancreatic body and tail cancer and greater preoperative serum carbohydrate antigen 19-9 levels than the negative cytology status group (P < .001 each). The ratio of peritoneal recurrence tended to be greater in the positive cytology status group (14% vs 43%; P < .001). Overall median survival times were less in the positive cytology status group (17.5 months vs 29.4 months; P < .001). The 5-year survival rates were 13.7% and 31.1% in the positive cytology status and negative cytology status groups, respectively. Multivariate analysis of positive cytology status patients revealed that adjuvant chemotherapy was an independent prognostic factor. CONCLUSION: Positive cytology status was an adverse prognostic factor in patients who underwent resection for pancreatic ductal adenocarcinoma but did not preclude attempted curative resection. Curative resection followed by adjuvant chemotherapy may contribute to long-term prognosis in patients with positive cytology status.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Tsuchida H, Fujii T, Mizuma M, et al. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society. Surgery. 2019. PMID: 31445763. doi:10.1016/j.surg.2019.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。